HIV Testing, Prevention and Care Interventions

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 8925

Special Issue Editors


E-Mail Website
Guest Editor
Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador
Interests: HIV testing; HIV treatment; pharmacology; infectious diseases; global health; neglected diseases; pharmacogenetics

E-Mail Website
Guest Editor
Director Donald Price Center Department of Global Health College of Public Health University of South Florida, Tampa, FL 33620, USA
Interests: vaccine; vaccinology; epidemiology; infectious diseases; public health; emerging infectious diseases; tropical neglected diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infection by human immunodeficiency virus (HIV) is a growing problem all around the world that, if not diagnosed and treated early, might cause acquired immunodeficiency syndrome (AIDS), the most advanced stage of HIV infection. Worldwide strategy promoted by the World Health Organization (WHO) and the United Nations UNAIDS focuses on 95% of people living with HIV knowing their status, 95% of people diagnosed with HIV being on antiretroviral therapy, and 95% of people on ART achieving viral suppression. It is well known that risk factors for HIV include having vaginal or anal sex with someone who is HIV positive or whose HIV status you do not know; having sex with many partners; and injecting drugs and sharing needles, syringes, or other drug equipment with others. For example, the Centers for Disease Control and Prevention (CDC) in the US recommends that everyone 13 to 64 years of age get tested for HIV at least once as part of routine health care and that people at higher risk for HIV get tested more often. If you are over 64 years of age and at risk for HIV, your health care provider may recommend HIV testing. Additionally, the CDC recommends that all pregnant women get tested for HIV so that they can begin taking HIV medicines if they are HIV positive. In addition, to achieve viral suppression, it is crucial to the laboratory monitoring of this parameter in the person living with HIV.

However, full access to testing is not possible everywhere, not necessarily due to lack of resources, as there are legal, cultural, and even religious barriers, plus the stigma, of course. For those reasons, this Special Issue is primarily focused on sharing experiences and pitfalls in one’s own reality to overcome HIV testing barriers, and those strategies to set proper prevention and care interventions.

In addition, this Special Issue aims to be enriched with quantitative data, rather than descriptive studies, to provide additional tools for decision makers on the important public health aspects concerning HIV-infected people, particularly to ensure that HIV is completely controlled and improve awareness in the HIV-negative population.

Prof. Dr. Enrique Terán
Dr. Ricardo Izurieta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV testing
  • HIV stigma
  • HIV prevention
  • HIV care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 356 KiB  
Article
Prevalence and Risk Factors of HIV Drug Resistance in Zimbabwe: Evidence from Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2020 Survey
by Munyaradzi Mapingure, Solomon Mukwenha, Innocent Chingombe, Rutendo Birri Makota, Elliot Mbunge, Enos Moyo, Garikayi Chemhaka, John Batani, Brian Moyo and Godfrey Musuka
Trop. Med. Infect. Dis. 2024, 9(11), 257; https://doi.org/10.3390/tropicalmed9110257 - 28 Oct 2024
Viewed by 947
Abstract
(1) Background: HIV drug resistance (HIVDR) poses a significant challenge to the effectiveness of antiretroviral therapy and the overall management of HIVand AIDS. Understanding the predictors of HIVDR is critical for developing strategies to mitigate its impact. The objectives of this study were [...] Read more.
(1) Background: HIV drug resistance (HIVDR) poses a significant challenge to the effectiveness of antiretroviral therapy and the overall management of HIVand AIDS. Understanding the predictors of HIVDR is critical for developing strategies to mitigate its impact. The objectives of this study were to identify the predictors of HIVDR among Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA 2020) study participants, a national population-based survey. (2) Methods: Data from people living with HIV who participated in the ZIMPHIA 2020 were used to determine the predictors of HIVDR. (3) Results: The prevalence of HIVDR was 44.9%. Acquired HIVDR was present in 76.1% of people with a virological failure and transmitted resistance is 22.6% in naïve individuals. Factors associated with HIVDR in adjusted analysis were the number of lifetime sexual partners (aOR = 1.03, 95% CI: 1.01–1.06, p = 0.017), each additional year since the first HIV positive result (aOR = 1.17, 95% CI: 1.09–1.25, p < 0.01), each additional year on ART (aOR = 1.14, 95% CI: 1.06–1.23, p = 0.001), initiating ART before 2014 (aOR = 3.08, 95% CI: 1.72–5.49, p = 0.020), ever had switched antiretrovirals (aOR = 2.47, 95% CI: 1.15–5.29, p = 0.020) or had ever had a viral load test (aOR = 2.54, 95% CI: 1.54–4.17, p < 0.001) and a CD4 count < 350 (aOR = 2.04, 95% CI: 1.48–2.83, p < 0.01), while age ≥ 50 (aOR = 0.56, 95% CI: 0.32–0.98, 32 p = 0.04), condom use at last encounter (OR: 0.49, 95%CI: 0.33–0.73, p < 0.001), and not being on ART (aOR = 0.09, 95% CI: 0.06–0.13, p < 0.01) were associated with reduced odds of HIVDR. Conclusions: HIVDR was high among the participants. There is a need to address HIVDR and enhance the mechanisms already in place. This study introduces more information that would help in developing targeted interventions to prevent HIVDR and improve patient outcomes. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
Show Figures

Figure 1

11 pages, 260 KiB  
Article
Replacement Therapy with Blood Products in People Living with HIV
by Mihaela Cristina Olariu, Mihaela Adela Iancu, Mihai Hristu Olariu, Victoria Aramă, Mădălina Simoiu, Miruna Maria Cruceru, Ecaterina Constanta Barbu, Paul Balanescu and Mihai Lazar
Trop. Med. Infect. Dis. 2024, 9(9), 213; https://doi.org/10.3390/tropicalmed9090213 - 13 Sep 2024
Viewed by 778
Abstract
Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to [...] Read more.
Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to determine the frequency of cytopenias and coagulation deficiencies in PLWH as well as the need for replacement therapy with blood products. We sought to determine whether there is an association between severe anemia or thrombocytopenia (requiring replacement therapy) and CD4+T lymphocyte levels. All 29 patients were critically ill, with 27 out of 29 (93%) in advanced stages of HIV disease and 23 out of 29 (79%) having CD4+ lymphocyte counts below 200 cells/microL. Most patients were either late presenters (45%) or had been lost to follow-up (41%). In addition to HIV infection, various conditions that could alter hematologic parameters were associated, including co-infections with hepatitis viruses, tuberculosis at various sites, malignant diseases, sepsis, SARS-CoV-2 infection, or other opportunistic infections. No significant correlation was found between severe anemia or severe thrombocytopenia or coagulation deficiencies and the CD4+T lymphocyte count. Our data suggest that these hematological disorders in patients with advanced HIV infection are more likely to be associated comorbidities rather than the HIV infection per se. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
12 pages, 235 KiB  
Article
Awareness, Intention to Use Pre-Exposure Prophylaxis, and Factors Associated with Awareness among Men Who Have Sex with Men in the Republic of Korea
by Sarang Jang and Aeree Sohn
Trop. Med. Infect. Dis. 2024, 9(8), 170; https://doi.org/10.3390/tropicalmed9080170 - 25 Jul 2024
Viewed by 757
Abstract
This study assessed pre-exposure prophylaxis (PrEP) awareness, knowledge, and attitudes in a sample of 1389 men who have sex with men (MSM). Using a self-report survey, we measured PrEP knowledge mean scores, attitudes toward PrEP, and awareness rates to identify the key influences [...] Read more.
This study assessed pre-exposure prophylaxis (PrEP) awareness, knowledge, and attitudes in a sample of 1389 men who have sex with men (MSM). Using a self-report survey, we measured PrEP knowledge mean scores, attitudes toward PrEP, and awareness rates to identify the key influences on PrEP uptake. PrEP awareness among participants was 66.3%, with 33.7% having never heard of PrEP. Approximately 4.5% had previous experience with PrEP but were not current users, while only 2.7% reported that they were currently taking it. Logistic regression analysis revealed that the significant predictors of PrEP awareness were educational attainment, marital status, prior HIV testing knowledge, and attitudes toward PrEP. Several demographic factors were not significant predictors of intention to use PrEP; however, using the internet to meet partners, number of partners, HIV testing, positive attitudes, and reduced perceived barriers played a critical role in shaping PrEP use intentions. These findings highlight the critical role of targeted educational strategies and tailored public health messaging in enhancing the awareness and intention to use PrEP among MSM. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
12 pages, 394 KiB  
Article
Risk Screening Tools Could Potentially Miss HIV-Positive Individuals Who Seek Testing Services: A Secondary Program Data Analysis on the Performance Characteristics of an Adolescent and Adult HIV Risk Screening Tool in Uganda
by Marvin Lubega, Katherine Guerra, Megan Ginivan, Yewande Kamuntu, George Senyama, Andrew Musoke, Fiona Gambanga, Shaukat Khan, Geoffrey Taasi, Sylivia Nalubega and John Bosco Junior Matovu
Trop. Med. Infect. Dis. 2024, 9(2), 37; https://doi.org/10.3390/tropicalmed9020037 - 1 Feb 2024
Viewed by 1896
Abstract
Improving HIV testing efficiency saves financial and material resources for health. We conducted a secondary data analysis of routinely collected HIV risk-screening program data in Uganda, from October to November 2019, to determine the performance characteristics of the adolescent and adult HIV risk [...] Read more.
Improving HIV testing efficiency saves financial and material resources for health. We conducted a secondary data analysis of routinely collected HIV risk-screening program data in Uganda, from October to November 2019, to determine the performance characteristics of the adolescent and adult HIV risk screening tools in public health facilities. A total of 19,854 clients had been screened for HIV testing eligibility and tested for HIV. The overall positivity rate (cluster-weighted prevalence of HIV) among those screened was 4.5% (95% CI: 4.1–4.8) versus 3.71% (95% CI: 3.06–4.50) among those not screened. The sensitivity and specificity of the risk screening tool were 91% (95% CI: 89–93) and 25% (24.2–26), respectively. With screening, the number needed to test to identify one PLHIV was reduced from 27 to 22. Although risk screening would have led to a 24.5% (4825/19,704) reduction in testing volume, 9.3% (68/732) of PLHIV would have been missed and be misclassified as not eligible for testing. The cost saving per PLHIV identified was minimally reduced by 3% from USD 69 without screening to USD 66.9 with screening. Since the treatment-adjusted prevalence of HIV is dropping globally, overzealous use of risk screening tools to determine who to test or not carries the potential of missing PLHIV due to their limited specificity. We recommend the use of scientifically validated HIV risk screening tools, and a need to explore the use of HIV self-testing as a test for tirage to minimize misclassification of people who seek HIV testing services. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
Show Figures

Figure 1

13 pages, 6748 KiB  
Article
Patterns of Rising HIV Positivity in Northern Madagascar: Evidence of an Urgent Public Health Concern
by Kyle E. Robinson, Jackson K. Long, Mamantsara Fardine, Adriantiana M. Stephano, Andrew Walsh and Eric P. Grewal
Trop. Med. Infect. Dis. 2024, 9(1), 19; https://doi.org/10.3390/tropicalmed9010019 - 11 Jan 2024
Cited by 3 | Viewed by 2881
Abstract
Despite over two decades of progress against HIV/AIDS in adjacent sub-Saharan Africa, HIV rates and deaths due to AIDS are exponentially rising in Madagascar. Furthermore, a growing body of evidence suggests that, due to a scarcity of general-population screening data, even the startling [...] Read more.
Despite over two decades of progress against HIV/AIDS in adjacent sub-Saharan Africa, HIV rates and deaths due to AIDS are exponentially rising in Madagascar. Furthermore, a growing body of evidence suggests that, due to a scarcity of general-population screening data, even the startling increase demonstrated by official models vastly underestimates the true population prevalence of HIV. We aimed to implement a real-world HIV screening and treatment protocol to serve a general population stemming from across northern Madagascar. In collaboration with the Malagasy Ministry of Health, we provided point-of-care HIV screening and confirmatory testing for over 1000 participants from 73 towns, villages, and cities. We recorded an overall HIV prevalence of 2.94%. Notably, we observed a 13.1% HIV prevalence rate among urban populations and showed that proximity to a major route of travel was significantly associated with HIV risk. We also observed a link between HIV risk and various occupations, including those associated with increased mobility (such as mining). Importantly, all HIV-positive individuals were initiated on antiretroviral therapy in concordance with local health authorities. To our knowledge, this study marks the largest primary test data-based HIV study to date among Madagascar’s general population, showing a greatly higher HIV prevalence (2.9%) than previously reported modeling-based figures (0.4%). Our rates aligned with the pattern of higher prevalence demonstrated in smaller general-population screening studies occurring more commonly prior to political strife in the mid-2000s. These findings demonstrate evidence of a growing HIV epidemic in northern Madagascar and underscore the need for future investment into more comprehensive HIV screening and control initiatives in Madagascar. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
Show Figures

Figure 1

Back to TopTop